Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.50 |
| ▸ | OTC | P00480 | 1/20 | 0.49 |
| ▸ | NOS2 | P35228 | 6/20 | 0.47 |
| ▸ | NOS1 | P29475 | 4/20 | 0.47 |
| ▸ | NOS3 | P29474 | 3/20 | 0.47 |
| ▸ | DDAH1 | O94760 | 3/20 | 0.46 |
| ▸ | ARG2 | P78540 | 4/20 | 0.46 |
| ▸ | ARG1 | P05089 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.44 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4225043 | 1.00 | GSR (0.50) | GSROTCNOS2NOS1NOS3 | |
| SCHEMBL4225929 | 1.00 | GSR (0.50) | GSROTCNOS2NOS1NOS3 | |
| SCHEMBL4221548 | 1.00 | GSR (0.50) | GSROTCNOS2NOS1NOS3 | |
| SCHEMBL43287 | 0.98 | GSR (0.52) | GSROTCNOS2NOS1NOS3 | |
| SCHEMBL28754154 | 0.98 | GSR (0.52) | GSROTCNOS2NOS1NOS3 | |
| SCHEMBL10071054 | 0.98 | GSR (0.52) | GSROTCNOS2NOS1NOS3 | |
| SCHEMBL880728 | 0.98 | GSR (0.52) | GSROTCNOS2NOS1NOS3 | |
| SCHEMBL27615800 | 0.98 | GSR (0.52) | GSROTCNOS2NOS1NOS3 | |
| Arginine SCHEMBL5152371 | 0.96 | OTC (0.53) | GSROTCNOS2NOS1NOS3 | |
| Hydrochloric Acid SCHEMBL21045047 | 0.96 | GSR (0.50) | GSROTCNOS2NOS1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11179471-B2 | Peptide for cytosolic delivery | KYOTO UNIVERSITY (JP) | 2021-11-23 | — | — | US | claimed |
| US-20200046840-A1 | PEPTIDE FOR CYTOSOLIC DELIVERY | KYOTO UNIVERSITY (JP) | 2020-02-13 | — | — | US | claimed |
| EP-3604520-A1 | PEPTIDE FOR CYTOSOLIC DELIVERY | Kyoto University (JP) | 2020-02-05 | — | — | EP | claimed |
| US-11179471-B2 | Peptide for cytosolic delivery | KYOTO UNIVERSITY (JP) | 2021-11-23 | — | — | US | disclosed |
| US-20200046840-A1 | PEPTIDE FOR CYTOSOLIC DELIVERY | KYOTO UNIVERSITY (JP) | 2020-02-13 | — | — | US | disclosed |
| EP-3604520-A1 | PEPTIDE FOR CYTOSOLIC DELIVERY | Kyoto University (JP) | 2020-02-05 | — | — | EP | disclosed |
| US-20090180958-A1 | Diagnostic and therapeutic agents | KARYON-CTT LTD. (FI) | 2009-07-16 | — | — | US | disclosed |
| EP-1874800-A1 | DIAGNOSTIC AND THERAPEUTIC AGENTS | Karyon-CTT Ltd (FI) | 2008-01-09 | — | — | EP | disclosed |
| US-20060275213-A1 | Tumor targeting agents and uses thereof | KARYON OY (FI) | 2006-12-07 | — | — | US | disclosed |
| US-20060263294-A1 | Tumor targeting agents and uses thereof | KARYON OY (FI) | 2006-11-23 | — | — | US | disclosed |
| WO-2006114478-A1 | DIAGNOSTIC AND THERAPEUTIC AGENTS | KARYON-CTT LTD (FI) | 2006-11-02 | — | — | WO | disclosed |
| EP-1549667-A1 | TUMOR TARGETING AGENTS AND USES THEREOF | Karyon OY (FI) | 2005-07-06 | — | — | EP | disclosed |
| EP-1549668-A1 | TUMOR TARGETING AGENTS AND USES THEREOF | Karyon OY (FI) | 2005-07-06 | — | — | EP | disclosed |
| EP-1549669-A1 | TUMOR TARGETING AGENTS AND USES THEREOF | Karyon OY (FI) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004031221-A9 | TUMOR TARGETING AGENTS AND USES THEREOF | KARYON OY (FI) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004031221-A1 | TUMOR TARGETING AGENTS AND USES THEREOF | KARYON OY (FI) | 2004-04-15 | — | — | WO | disclosed |
| WO-2004031218-A1 | TUMOR TARGETING AGENTS AND USES THEREOF | KARYON OY (FI) | 2004-04-15 | — | — | WO | disclosed |
| WO-2004031219-A1 | TUMOR TARGETING AGENTS AND USES THEREOF | KARYON OY (FI) | 2004-04-15 | — | — | WO | disclosed |
| WO-2004031220-A1 | TUMOR TARGETING AGENTS AND USES THEREOF | KARYON OY (FI) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060275213-A1 | Tumor targeting agents and uses thereof | CCL2, CCL5, SCTR | GSR 4146/4885OTC 3603/4885NOS2 4461/4885 |
| US-20090180958-A1 | Diagnostic and therapeutic agents | TPX2, ZFX, ZYX | GSR 1377/4885OTC 3137/4885NOS2 4646/4885 |
| US-20060263294-A1 | Tumor targeting agents and uses thereof | CRACR2A, FGB, EWSR1 | GSR 3035/4885OTC 2421/4885NOS2 2998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.